Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3292829 | Gastroenterology | 2014 | 15 Pages |
Abstract
Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54. Safety was consistent with that reported for other TNFα antagonists and golimumab in other approved indications. ClinicalTrials.gov number: NCT00488631.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
William J. Sandborn, Brian G. Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J. Adedokun, Cynthia Guzzo, Jean-Frederic Colombel, Walter Reinisch, Peter R. Gibson, Judith Collins, Gunnar Järnerot, Paul Rutgeerts,